116 related articles for article (PubMed ID: 15331914)
1. Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding.
Mahar Doan KM; Wring SA; Shampine LJ; Jordan KH; Bishop JP; Kratz J; Yang E; Serabjit-Singh CJ; Adkison KK; Polli JW
Pharmacology; 2004 Oct; 72(2):92-8. PubMed ID: 15331914
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine.
Polli JW; Baughman TM; Humphreys JE; Jordan KH; Mote AL; Salisbury JA; Tippin TK; Serabjit-Singh CJ
J Pharm Sci; 2003 Oct; 92(10):2082-9. PubMed ID: 14502547
[TBL] [Abstract][Full Text] [Related]
3. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys.
Tang C; Kuo Y; Pudvah NT; Ellis JD; Michener MS; Egbertson M; Graham SL; Cook JJ; Hochman JH; Prueksaritanont T
Biochem Pharmacol; 2009 Sep; 78(6):642-7. PubMed ID: 19481060
[TBL] [Abstract][Full Text] [Related]
4. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Mahar Doan KM; Humphreys JE; Webster LO; Wring SA; Shampine LJ; Serabjit-Singh CJ; Adkison KK; Polli JW
J Pharmacol Exp Ther; 2002 Dec; 303(3):1029-37. PubMed ID: 12438524
[TBL] [Abstract][Full Text] [Related]
5. The impact of P-glycoprotein mediated efflux on absorption of 11 sedating and less-sedating antihistamines using Caco-2 monolayers.
Crowe A; Wright C
Xenobiotica; 2012 Jun; 42(6):538-49. PubMed ID: 22188412
[TBL] [Abstract][Full Text] [Related]
6. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios.
Kalvass JC; Maurer TS; Pollack GM
Drug Metab Dispos; 2007 Apr; 35(4):660-6. PubMed ID: 17237155
[TBL] [Abstract][Full Text] [Related]
7. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain.
Summerfield SG; Stevens AJ; Cutler L; del Carmen Osuna M; Hammond B; Tang SP; Hersey A; Spalding DJ; Jeffrey P
J Pharmacol Exp Ther; 2006 Mar; 316(3):1282-90. PubMed ID: 16330496
[TBL] [Abstract][Full Text] [Related]
8. Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study.
de Vries EF; Doorduin J; Vellinga NA; van Waarde A; Dierckx RA; Klein HC
Nucl Med Biol; 2008 May; 35(4):459-66. PubMed ID: 18482683
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.
Tahara H; Kusuhara H; Fuse E; Sugiyama Y
Drug Metab Dispos; 2005 Jul; 33(7):963-8. PubMed ID: 15821041
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein.
Obradovic T; Dobson GG; Shingaki T; Kungu T; Hidalgo IJ
Pharm Res; 2007 Feb; 24(2):318-27. PubMed ID: 17180728
[TBL] [Abstract][Full Text] [Related]
11. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport.
Varma MV; Sateesh K; Panchagnula R
Mol Pharm; 2005; 2(1):12-21. PubMed ID: 15804173
[TBL] [Abstract][Full Text] [Related]
12. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.
He H; Lyons KA; Shen X; Yao Z; Bleasby K; Chan G; Hafey M; Li X; Xu S; Salituro GM; Cohen LH; Tang W
Xenobiotica; 2009 Sep; 39(9):687-93. PubMed ID: 19569734
[TBL] [Abstract][Full Text] [Related]
13. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
Feng B; Mills JB; Davidson RE; Mireles RJ; Janiszewski JS; Troutman MD; de Morais SM
Drug Metab Dispos; 2008 Feb; 36(2):268-75. PubMed ID: 17962372
[TBL] [Abstract][Full Text] [Related]
14. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice.
Gallo JM; Li S; Guo P; Reed K; Ma J
Cancer Res; 2003 Aug; 63(16):5114-7. PubMed ID: 12941842
[TBL] [Abstract][Full Text] [Related]
15. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A.
Peng SX; Ritchie DM; Cousineau M; Danser E; Dewire R; Floden J
J Pharm Sci; 2006 Sep; 95(9):1984-93. PubMed ID: 16850393
[TBL] [Abstract][Full Text] [Related]
16. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
Regev R; Katzir H; Yeheskely-Hayon D; Eytan GD
FEBS J; 2007 Dec; 274(23):6204-14. PubMed ID: 17986257
[TBL] [Abstract][Full Text] [Related]
17. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
Gnoth MJ; Sandmann S; Engel K; Radtke M
Drug Metab Dispos; 2010 Aug; 38(8):1341-6. PubMed ID: 20413726
[TBL] [Abstract][Full Text] [Related]
18. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines.
Chishty M; Reichel A; Siva J; Abbott NJ; Begley DJ
J Drug Target; 2001 Jun; 9(3):223-8. PubMed ID: 11697207
[TBL] [Abstract][Full Text] [Related]
19. Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.
Loureiro AI; Bonifácio MJ; Fernandes-Lopes C; Pires N; Igreja B; Wright LC; Soares-da-Silva P
Xenobiotica; 2015; 45(9):828-39. PubMed ID: 25915108
[TBL] [Abstract][Full Text] [Related]
20. Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions?
Collett A; Tanianis-Hughes J; Warhurst G
Biochem Pharmacol; 2004 Aug; 68(4):783-90. PubMed ID: 15276086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
